ChemoCentryx is a focused pharmaceutical company creating first-in-class, orally available medicines for autoimmune diseases, inflammatory disorders and oncology. By leveraging their pioneering expertise in the field of chemokine research, ChemoCentryx has generated a broad portfolio of medicines targeting the chemokine system, with six product candidates currently in pre-clinical and clinical stages of development.
Select Venture Capital & Financial Partners
Alta PartnersGlaxoSmithKlineHBM BioVenturesHealthCap Venture CapitalJennison AssociatesOrbiMed AdvisorsSilicon Valley Bank